Bayer Healthcare announced plans to further develop its plant in Berkeley, CA. Expansion of the plant will result in new jobs, a broader base of operations along with the designation as one of Bayer’s three worldwide research and development sites. As part of an overall restructuring plan, which is projected for completion by mid-2007, Bayer is also closing its Berlex Biosciences facility in Richmond, CA.
“It’s a really good time for the Berkeley location,” said Bayer Spokesperson Sreejit Mohan. “More and better opportunities to work in a lot of different areas that we didn’t work on before.”
Research at the Berkeley location will concentrate on protein-related therapies. The plant will continue to manufacture Kogenate FS®, Bayer’s recombinant factor VIII product.
Source: The Daily Californian, November 14, 2006